Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalence

被引：6

作者：

Namujju P.B. ^{[1
,2
,3
]}

Hedman L. ^{[4
]}

Hedman K. ^{[4
]}

Banura C. ^{[5
]}

Mbidde E.K. ^{[2
]}

Kizito D. ^{[2
]}

Byaruhanga R.N. ^{[6
,7
]}

Muwanga M. ^{[8
]}

Kirnbauer R. ^{[9
]}

Surcel H.-M. ^{[1
]}

Lehtinen M. ^{[3
]}

机构：

[1] National Institute for Health and Welfare, Oulu

[2] Uganda Virus Research Institute, Entebbe

[3] School of Public Health, University of Tampere

[4] Department of Virology, University of Helsinki and Huslab, Helsinki

[5] College of Health Sciences, Makerere University, Kampala

[6] Department of Obstetrics and Gynecology, San Raphael of St. Francis Hospital, Nsambya

[7] Department of Public Health Sciences, Karolinska Institute, Stockholm

[8] Entebbe Hospital, Entebbe

[9] Department of Dermatology, Medical University Vienna

来源：

BMC Research Notes | / 4卷 / 1期

关键词：

antibody; avidity; genital infection; HPV; prevalence;

D O I：

10.1186/1756-0500-4-170

中图分类号：

学科分类号：

摘要：

Background: Low avidity of antibodies against viral, bacterial and parasitic agents has been used for differential diagnosis of acute versus recent/past infections. The low-avidity antibodies may however, persist for a longer period in some individuals. Findings. We studied the association of human papillomavirus (HPV) type 16 antibody avidity with seroprevalence to HPV types 6/11/18/31/33/45. Antibody avidity was analysed for 365 HPV16 seropositive pregnant Finnish and Ugandan women using a modified ELISA. Low avidity of HPV16 antibodies was found in 15% of Finnish and 26% of Ugandan women. Ugandan women with low-avidity HPV16 antibodies had an increased risk estimate for HPV6/11 (odds ratio, OR 2.9; 95%CI 1.01-8.4) seropositivity but not to high-risk HPV types 18/31/33/45. Conclusion: Association of the low avidity HPV16 antibody phenotype with possible susceptibility to infections with other HPV types warrants investigation. © 2011 Namujju et al; licensee BioMed Central Ltd.""

引用

共 32 条

[1] Ferlay J., Bray F., Pisani P., Parkin M.D., GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide, IARC Cancer Base, (2004)
[2] Walboomers J.M.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J.F., Peto J., Meijer C.J.L.M., Munoz N., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, Journal of Pathology, 189, 1, pp. 12-19, (1999)
[3] Ho G.Y.F., Studentsov Y., Hall C.B., Bierman R., Beardsley L., Lempa M., Burk R.D., Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles, Journal of Infectious Diseases, 186, 6, pp. 737-742, (2002)
[4] Trottier H., Mahmud S., Costa M.C., Sobrinho J.P., Duarte-Franco E., Rohan T.E., Ferenczy A., Villa L.L., Franco E.L., Human papillomavirus infections with multiple types and risk of cervical neoplasia, Cancer Epidemiology Biomarkers and Prevention, 15, 7, pp. 1274-1280, (2006)
[5] Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., Perez G., Koutsky L.A., Tay E.H., Garcia P., Et al., The impact of quadrivalent human papillomavirus (HPV
[6] Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years, J Infect Dis, 199, pp. 926-35, (2009)
[7] Paavonen J., Naud P., Salmeran J., Wheeler C.M., Chow S.N., Apter D., Kitchener H., Castellsague X., Teixeira J.C., Skinner S.R., Et al., Efficacy of human papillomavirus (HPV)-16/18AS04-adjuvanted vaccine against cervical infection andprecancer caused by oncogenic HPV types (PATRICIA):final analysis of a double-blind, randomised study inyoung, Lancet, 374, pp. 301-14, (2009)
[8] Villa L., Perez G., Kjaer S., Lehtinen M., Paavonen J., Munoz N., Sigurdsson K., Hernandez-Avila M., Iversen O.E., Thoresen S., Et al., Prophylactic use of human papillomavirus (HPV) L1 virus-like particle vaccine significantly reduces intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ risk, Lancet, 369, pp. 1861-8, (2007)
[9] Auvinen E., Niemi M., Malm C., Zilliacus R., Trontti A., Fingerroos R., Lehtinen M., Paavonen J., High prevalence of HPV among female students in Finland, Scand J Infect Dis, 37, pp. 873-6, (2005)
[10] Banura C., Franceschi S., Van Doorn L.J., Arslan A., Kleter B., Wabwire-Mangen F., Mbidde E.K., Quint W., Weiderpass E., Prevalence, incidence and clearance of human papillomavirus infection among young primiparous pregnant women in Kampala, Uganda, Int J Cancer, 123, pp. 2180-7, (2008)

← 1 2 3 4 →